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Introduction {#sec001}
============

The protein energy wasting (PEW) syndrome, including muscle atrophy, is frequently encountered in hemodialysis patients and contributes to the high mortality rate observed in this population \[[@pone.0236948.ref001]\]. It can be caused by a decrease in energy and protein intakes, sedentariness, hormonal disorders, metabolic acidosis and inflammation. The decrease in muscle mass is due to an imbalance in protein synthesis and proteolysis in favor of the latter \[[@pone.0236948.ref002]\]. The ubiquitin-proteasome proteolytic system (UPS) is crucial for the atrophying process, notably in chronic kidney disease (CKD) \[[@pone.0236948.ref003], [@pone.0236948.ref004]\]. The first step in myofibrillar protein degradation is thought to be activation of caspase 3 \[[@pone.0236948.ref005]\]. The UPS then targets the proteins to be degraded, (such as myosin \[[@pone.0236948.ref006]\] and actin \[[@pone.0236948.ref007]\], by linking covalently a ubiquitin (Ub) chain. Ub chain formation is catalyzed by an enzymatic cascade (E1, E2, E3), with E3s that recognize the substrates. The 26S proteasome consists of a core particle with proteolytic activity (proteasome 20S) and two regulator particles (proteasome 19S) at its extremities \[[@pone.0236948.ref008]\]. The 26S proteasome recognizes and degrades polyubiquitinated proteins. In animal models of CKD-induced muscle atrophy, studies of muscle biopsies have shown an increase in the 14kDa actin level, a **"**footprint" of caspase 3 activity \[[@pone.0236948.ref005]\], increased expression of E3 ligases such as the muscle- specific E3 ligases MuRF1 and MAFbx \[[@pone.0236948.ref009], [@pone.0236948.ref010]\], and proteasome subunits\[[@pone.0236948.ref011]\]. In humans, activation of the UPS is evidenced by an increased expression of several E3 ligases in the muscle of hemodialysis patients \[[@pone.0236948.ref004]\]. However, it is not possible to perform a muscle biopsy in all patients to detect the activation of UPS. This is why the identification of biomarkers associated with the onset of muscle wasting and that are easily measurable in the blood would be more useful. 20S proteasome measured in plasma by ELISA seems a good candidate for this assessment. Increases in circulating 20S proteasome (c20S proteasome) have been widely reported in hematologic malignancies, solid cancers, burn injury, sepsis and autoimmune diseases. c20S proteasome levels are associated with poor prognosis and increased mortality in this setting \[[@pone.0236948.ref012]\]. To date only one study, by *Fukasawa et al*., has looked at the c20S proteasome as a marker of muscle atrophy. The authors found a weak but significant correlation in hemodialysis patients between c20S proteasome, abdominal muscle area measured by computed tomography and creatinine production \[[@pone.0236948.ref013]\]. Thus, we hypothesized that an increase in the c20S proteasome level could predict the evolution of PEW parameters and patient outcomes. The aim of this study was to determine whether a c20S proteasome assay is predictive of muscle mass loss and PEW in hemodialysis patients.

Material and method {#sec002}
===================

Study design and subjects {#sec003}
-------------------------

We conducted a prospective cohort study at the dialysis center of the university hospital of Clermont-Ferrand (France). Patients over 18 years old and treated by hemodialysis or hemodiafiltration for more than 3 months were selected. Exclusion criteria were lack of consent, acute infection or inflammatory disease during the 3 months before inclusion, serum C reactive protein level (CRP) \> 30 mg/L, active malignancy disease, hypercortisolism, uncontrolled dysthyroidism and neuromuscular pathology. Patients were followed from March 2016 to March 2018 or death or until transplantation, transfer to another center or the end of follow-up (march 20). The study protocol has been reviewed and approved by the local research ethic committee, (CPP Sud-Est VI, no. 2016-AU1246) and the French national agency for the safety of medicines and health products (IDRCB: 2016-A00204-47). All patients provided written informed consent before participation.

Biochemical and clinical measurements {#sec004}
-------------------------------------

Demographic and clinical data (gender, age, cause of end stage renal diseases, dialysis vintage, technique and comorbidities) were obtained at baseline from medical records. The date and cause of death, number of hospitalizations, dates and causes of admission were collected over 2 years. Blood samples were drawn at the start and the end of the middle week dialysis sessions at baseline, and after 1 and 2 years of follow-up. Urea and creatinine serum levels before and after dialysis sessions, albumin, prealbumin, bicarbonate, hemoglobin, CRP, parathyroid hormone (PTH), vitamin D, iron, ferritin and transferin serum levels were measured by standard laboratory techniques with an auto-analyzer.

Anthropometric measurements {#sec005}
---------------------------

Anthropometric measurements (body weight, height, mid-arm circumference, triceps skinfold thickness) were performed after a mid-week dialysis session at inclusion and at 1 year and 2 years. Body mass index (BMI) was calculated with the ratio body weight /size^2^ (kg/m^2^) and mid-arm muscle circumference (MAMC) with the following formula: mid-arm circumference-- 3.142 x triceps skinfold thickness (cm).

Bioimpedancemetry {#sec006}
-----------------

Body composition \[adipose tissue mass (ATM), lean tissue mass (LTM), fat tissue Index (FTI), lean tissue index (LTI) and overhydration (OW)\] was evaluated at inclusion, 1 year and 2 years by multifrequence bioimpedancemetry using a Body Composition Monitor (BCM ® Fresenius Medical Care, Bad Homburg, Germany). Measurements were performed after 10 minutes of rest in the lying position, before the start of a mid-week dialysis session.

Proteasome measurement {#sec007}
----------------------

C20S proteasome was measured by enzyme-linked immunosorbent assay (ELISA) using the proteasome ELISA kit (Enzo Life Sciences, Farmingdale, New York, United-States) at inclusion and at the end of follow-up. As previously reported \[[@pone.0236948.ref013]\], 5 ml of blood were drawn before a mid-week dialysis session in a dry tube with separating gel and then centrifuged. Aliquots were then prepared and stored at -20°C. The ELISA plate is coated with the capture antibody. The detection antibody is then added, followed by the secondary antibody conjugated with horseradish peroxidase. Peroxydase reacts with TMB (3, 3\', 5, 5\'-tetramethylbenzidine) substrate to produce a blue solution. The color intensity at 450 nm is directly proportional to proteasome concentration.

Formula and calculated scores {#sec008}
-----------------------------

Kt/V~sp~ was calculated with the formula of *Daugirdas et al* to evaluate dialysis dose: Kt/V~sp~ = ln (R---0.008 × t) + (4--3.5 × R) × 0.55 UF/W, where R is the ratio of postdialysis to predialysis urea level, UF the ultrafiltration volume and W the post-dialysis body weight \[[@pone.0236948.ref014]\]. Normalized protein catabolic rate (nPCR) was calculated according to the model of *Depner et al*: nPCR (g/kg/day) = (Urea × 2.801) / (25.8 + 1.15 Kt/V~sp~ + 56.4/ Kt/V~sp~) + 0.168. Urea is serum urea (mmol/L) before dialysis \[[@pone.0236948.ref015]\]. Creatinine index was calculated according to *Canaud et al* with the following formula: creatinine index (mg/kg/day): 16.21 + 1.12 × \[1 (male); 0 (female)\]- 0.06 × age---0.08 × Kt/V~sp~ + 0.009 × creatinine, age in years, creatinine in μmol/L \[[@pone.0236948.ref016]\]. The Prognostic Inflammatory and Nutritional Index (PINI) was calculated by the following formula: PINI = (alpha1-Acid Glycoprotein (α-AG) = orosomucoid in mg/L × CRP mg/L) / (albumin in g/L × prealbumin in mg/L)\[[@pone.0236948.ref017]\]. Protein energy wasting syndrome (PEW) was defined according to guidelines of the International Society of Renal Nutrition and Metabolism (ISRNM) \[[@pone.0236948.ref018]\]. However, energy and protein intakes are not routinely collected in our center and nPCR was used to assess protein intake. A simplified definition of PEW was used \[[@pone.0236948.ref019]\] based on fewer than three of the following items: albumin \> 35g/dl, BMI \> 23kg/m^2^, serum creatinine/body surface area (BSA) \> 380 μmol/l/m^2^ (with BSA estimated using Boyd formula) and nPCR \> 0.8g/kg/day.

Statistical analysis {#sec009}
--------------------

All statistical analyses were performed with Stata software (version 13, Statacorp, College Station, US). The tests were two-sided with a type-I error set at 5%. Categorical data were presented as numbers and percentages and continuous data as mean ± standard-deviation (SD) or median (interquartile range) according to the statistical distribution. The assumption of normality was assessed by the Shapiro-Wilk test. Univariate analyses were then carried out to compare variables between independent groups using Student t-test or Mann-Whitney test when the hypotheses of t-test were not met for continuous parameters and Chi2 test or, if applicable, Fisher\'s exact test for categorical variables. The study of relations between continuous variables was analyzed estimating correlation coefficient, Pearson or Spearman according to the statistical distribution and applying a Sidak's type I error correction to take into account multiple comparisons. Survival was estimated by the Kaplan-Meier method. To identify prognostic predictors, comparisons were performed with the log-rank test in univariate analyses and Cox proportional-hazards regression. The proportional-hazard hypothesis was tested by Schoenfeld's test and plotting residuals.

Results {#sec010}
=======

Baseline characteristics {#sec011}
------------------------

At the start of the study, 96 patients were being treated in our center, of whom 49 were enrolled and followed. A flow chart is provided in [Fig 1](#pone.0236948.g001){ref-type="fig"}.

![Flow chart.\
CRP, C-reactive protein.](pone.0236948.g001){#pone.0236948.g001}

Baseline characteristic of the patients are shown in [Table 1](#pone.0236948.t001){ref-type="table"}. The cause of ESRD was chronic glomerulonephritis (35%), vascular nephropathy (18%), polycystic kidney disease (10%), diabetic nephropathy (4%) and other/unknown (35%). Four (8%) patients were being treated with perdialytic parenteral nutrition and 21 (45%) with oral nutritional supplements. Three (6%) patients had Kt/V~sp~ \< 1.2, 6 (12%) patients had a predialysis bicarbonate blood level below 22 mmol/L, 9 (18%) a PTH level above nine times the upper limit of normal value, and 18 (37%) had a 25OH Vitamin D3 \< 30 μg/L.

10.1371/journal.pone.0236948.t001

###### Baseline characteristics.

![](pone.0236948.t001){#pone.0236948.t001g}

  Characteristics                         Value
  --------------------------------------- ------------------
  Age (years)                             68.7 ± 12.3
  Female, n (%)                           17 (35)
  BMI (kg/m^2^)                           26.5 ± 6.3
  Diabetes, n (%)                         16 (33)
  Dialysis vintage (months)               38 \[15--58\]
  Time dialysis session (hours)           4.1 ± 0.3
  Kt/V                                    1.8 ± 0.3 
  Urea (mmol/l)                           21.0 ± 6.4
  Creatinine (μmol/l)                     708 ± 172
  Bicarbonate (mmol/l)                    23.8 ± 2.4
  Plasma proteins (g/l)                   68.0 ± 5.6
  Hemoglobin (g/dl)                       12.0 ± 1.2
  Parathyroid hormone (ng/l)              484 \[168--608\]
  Vitamin D (μg/l)                        34.1 ± 16.5
  Transferrin saturation coefficient, %   30.3 ± 8.8
  Ferritin (ng/L)                         474 ± 255
  CRP (mg/l)                              6.6 ± 7.9

BMI, body mass index; CRP, C-reactive protein.

Values of nutritional markers at inclusion are shown in [Table 2](#pone.0236948.t002){ref-type="table"}. BMI \< 23 was observed in 13 (27%) patients. Patients had a serum albumin \< 35 g/L or a serum prealbumin \< 0.30 g/L in 41% and 47% of cases, respectively. Low muscle mass as defined by a LTI \< 10th was observed in 16 (33%) patients. PINI \> 1 was recorded in 15 (31%) patients, and PEW in 24 (49%) and 30 (61%) patients according to ISRNM or simplified definition, respectively.

10.1371/journal.pone.0236948.t002

###### Baseline values of nutritional markers.

![](pone.0236948.t002){#pone.0236948.t002g}

                            Nutritional markers                 Mean value
  ------------------------- ----------------------------------- -------------
  **Biochemical markers**   Albumin (g/l)                       35.7 ± 3.4
                            Prealbumin (g/l)                    0.3 ± 0.1
  **Body mass**             BMI (kg/m^2^)                       26.5 ± 6.3
                            Triceps skinfold thickness (mm)     16.0 ± 9.4
                            FTI (kg/m^2^)                       14.9 ± 6.7
                            ATM (kg)                            42.0 ± 17.9
  **Muscle mass**           Mid-arm circumference (cm)          31.1 ± 5.9
                            Mid-arm muscle circumference (cm)   25.5 ± 5.8
                            Creatinine index (mg/kg/day)        19.1 ± 2.1
                            LTI (kg/m^2^)                       12.7 ± 2.5
                            LTM (kg)                            35.5 ± 8.7
  **Dietary intakes**       nPCR (g/kg/day)                     1.1 ± 0.3

ATM, adipose tissue mass; BMI, body mass index; FTI, fat tissue index; LTI, lean tissue index; LTM, lean tissue mass; nPCR, normalized protein catabolic rate; PEW, protein energy wasting; PINI, prognostic inflammatory and nutritional index.

c20S proteasome and correlation with nutritional markers at baseline and during follow-up {#sec012}
-----------------------------------------------------------------------------------------

At inclusion, c20S proteasome level were 0.40\[0.26--0.55\] μg/ml. Pearson correlation coefficients between c20S proteasome levels and different nutritional parameters are resumed in [Table 3](#pone.0236948.t003){ref-type="table"}. Increased c20S proteasome level were positively related with LTI at baseline and negatively with 2 years LTI variation ([Fig 2](#pone.0236948.g002){ref-type="fig"}). C20S proteasome was not different in patients with PEW at baseline according ISRNM (0.42 ± 0.21 Vs 0.45 ± 0.19, p = 0.73) or according the simplified definition (0.39 ±0.19 Vs 0.51 ±0.22, p = 0.21) in comparison of patients without PEW.

![Linear regression between two years LTI variation and baseline c20S proteasome.\
c20S proteasome, circulating 20S proteasome; LTI, lean tissue index measured by multifrequence bioimpedancemetry.](pone.0236948.g002){#pone.0236948.g002}

10.1371/journal.pone.0236948.t003

###### Pearson correlation coefficient between c20S Proteasome at baseline and nutritional markers.

![](pone.0236948.t003){#pone.0236948.t003g}

                       Baseline value                                  1 year Variation   2 years Variation
  -------------------- ----------------------------------------------- ------------------ ------------------------------------------------
  *Dry weight*         0.14                                            0.03               0.08
  *BMI*                0.11                                            0.00               -0.04
  *LTI*                **0.43[\*](#t003fn002){ref-type="table-fn"}**   -0.06              **-0.56[\*](#t003fn002){ref-type="table-fn"}**
  *LTM*                **0.39[\*](#t003fn002){ref-type="table-fn"}**   0.34               **-0.54[\*](#t003fn002){ref-type="table-fn"}**
  *FTI*                0.20                                            0.06               **0.40[\*](#t003fn002){ref-type="table-fn"}**
  *ATM*                0.22                                            0.22               0.28
  *Creatinine Index*   0.14                                            -0.19              0.11
  *Albumin*            -0.10                                           0.24               0.12
  *Prealbumin*         0.17                                            0.23               0.18

ATM, adipose tissue mass; BMI, body mass index;; FTI, fat tissue index; LTI, Lean tissue index; LTM, lean tissue mass

**\*** p\<0.05.

c20S proteasome levels and patients outcomes {#sec013}
--------------------------------------------

During the follow-up period 11 patients died (22.9%), 3 patients died during the first year and 8 during the second year of follow-up. The causes of death were cardiac disease (n = 2), cerebral stroke (n = 1), neoplasia (n = 1), pulmonary embolism (n = 1), calciphylaxis (n = 1), hemorrhage (n = 1), hemodialysis withdrawal (n = 2) and unknown (n = 1). C20S proteasome level (HR = 1.124, 95%CI \[0.05--24.8\], p = 0.94) and a proteasome level above the median value (HR = 0.75, 95%CI \[0.21--2.59\], p = 0.63) did not predict patient survival at two years. Among nutritional markers, only a prealbumin level \< 30 g/L was associated with decreased patient survival at two years (HR = 5.1, 95%CI\[1.10--24.1\], p = 0.03) ([Fig 3](#pone.0236948.g003){ref-type="fig"}). During the follow-up, 28 patients were hospitalized. Admission rates did not differ between patients having above or under the median c20S proteasome value (p = 0.15).

![Two-year survival according to baseline c20S proteasome and prealbumin value.\
c20S proteasome, circulating 20S proteasome.](pone.0236948.g003){#pone.0236948.g003}

Discussion {#sec014}
==========

This study assessed the value of the c20S proteasome in the assessment of nutritional status, prediction of its evolution and its prognostic value in chronic hemodialysis patients. The baseline value of c20S proteasome was poorly but significantly positively related with LTI and increased c20S proteasome was predictive of muscle mass loss at two years. However, in this study c20S proteasome level did not seem predictive of patient outcome.

The presence of c20S proteasome in blood plasma was first reported by *Wada et al* in 1993 \[[@pone.0236948.ref020]\]. In the early 2000s its detection with ELISA was developed \[[@pone.0236948.ref021]\]. Since then c20S proteasome has been studied in several diseases. Elevated c20S proteasome is found in different solid tumors \[[@pone.0236948.ref022]\], hematological disease \[[@pone.0236948.ref023]\], critically ill patients \[[@pone.0236948.ref024]\], autoimmune diseases \[[@pone.0236948.ref025]\] and surgery \[[@pone.0236948.ref026]\] where it can be predictive of disease severity and/or patient outcomes. C20S proteasome is probably not specific to muscle mass or protein wasting and could reflect various mechanisms. The origin (white blood, cancer or injured cells) and role of the circulating proteasome are incompletely elucidated and need to be explored.

C20S proteasome levels in our study were quite low compared to those in the study of *Fukasawa et al* \[[@pone.0236948.ref013]\]: values of c20S proteasome level dosage, 1.34 ± 1.12 μg / mL (ELISA) and 1.33 ± 0.53 μg / mL (Western Blot) for CKD patients in the Japanese study, and 0.41 ± 0.31 (ELISA) in our study. The low c20S proteasome levels observed in our study cannot be explained by differences in assay methods since we used the same ELISA assay which had been correlated with Western Blot measurements. A second assay of the 20S proteasome was carried out in the remaining patients at the end of the 2 years of follow-up: it also found lower values than in the study of *Fukasawa et al* (0.6 ±0.16), which makes the assumption of an assay error unlikely.

In the study of *Fukasawa et al*, a negative correlation was found between c20S proteasome levels and abdominal muscle area (AMA) measured in axial CT images at the level of the third lumber spine. In contrast, in the present study we found a low but significant correlation between c20S proteasome levels and muscle mass measured by multifrequence bioimpedancemetry. It could be assumed that this was due to a different technique for measuring muscle mass but the measurement of the muscle area in the lumbar section and bioimpedancemetry are both fairly representative of muscle mass assessed by dual energy X-ray absorptiometry, which is the reference technique \[[@pone.0236948.ref027], [@pone.0236948.ref028]\]. In addition, in our study LTI and c20S proteasome assays were performed the same week. In the study of *Fukasawa et al*, the CT scan used for AMA measurement was not performed during the same week and the indication of this exam was not specified. In fact, the correlation coefficient reported was very low (R = 0.26 in univariate analysis and R = 0.19 in multivariate analysis). Hence, even if the relationship is statistically significant it is not clinically relevant. Moreover, as in our study, no correlation was found between the levels of c20S proteasome and other parameters conventionally used to assess nutritional status such as albumin level, creatinine, nPCR, BMI, IL-6, subcutaneous and visceral abdominal fat mass. In our study, the c20S proteasome levels were not related to decreased muscle mass or PEW criteria at baseline. Unexpectedly, we found a positive correlation between c20 proteasome and LTI at baseline whereas increased proteasome 20S was significantly related to a decrease in LTI at 2 years. Provided that the circulating proteasome originates from the muscle cell, this can be explained by the fact that the quantity released depends not only on the state of activation of the proteasome within each muscle fiber (i.e. muscle catabolic process) but also on the number of fibers (i.e. muscle mass).

Other new biological markers of muscle have been recently reported notably post-translationally modified muscle-specific ubiquitin ligases and miRNA \[[@pone.0236948.ref029]\]. In hemodialysis patients, myostatin and IGF1 have been shown to be correlated with HGS and MMI (muscle mass divided by body surface area measured by multifrequence impedancemetry). However, the correlation coefficients were low (R ^=^ 0.37 and 0.46, respectively) for HGS and MMI. Moreover, predialysis creatinine performed better. These parameters were associated with first-year mortality in univariate analysis but their effect was non-significant when adjusted for prealbumin \[[@pone.0236948.ref030]\]. Similar results were obtained in a subsequent study \[[@pone.0236948.ref031]\]. The use of a single marker may not be sufficient. A strategy based on the identification of a group of biomarkers could be more effective. Niewczas et al have recently shown that proteomic profiling of circulating protein identified 17 proteins enriched for TNF Receptor Superfamilly members and associated with a 10-years risk of end stage-renal disease in diabetic patients \[[@pone.0236948.ref032]\]. Given the role of inflammation in PEW and muscle atrophy it can be assumed that such an approach would be relevant to discover biomarkers associated with the risk of muscle mass loss.

This study has certain limitations. First, with regard to the definition of PEW on the basis of the ISRNM score, we had to adapt to the data available to arrive as close as possible to the initial definition. It is therefore not a fully validated score. Second, the limited number of patients included and the rate of loss of follow-up resulted in a lack of power so that results at 2 years should be viewed with caution. The power of the study was calculated using the seqtest R package. Thus the power to detect a clinically relevant correlation (R^2^\> 0.5) a type-I error set at 5% was 98.3% at inclusion, 97% at 1 year and 89% at two years. In addition, variability in the dosage of c20S proteasome in the hemodialysis population was very low and made it more difficult to demonstrate a correlation. Finally, overall, the nutritional markers varied little during follow-up. CKD-induced muscle atrophy is a very progressive process and it is possible that muscle mass will stabilize after a period of decrease. Also, although the measurement of c20S proteasome seems of little interest in CKD patients, it could be so in cases of acute kidney injury, where UPS activation has been observed in animal models \[[@pone.0236948.ref010]\].

In conclusion, c20S proteasome measurement does not seem to be of great value in assessing and predicting the evolution of nutritional status in hemodialysis patients. Muscle atrophy is the result of profound changes in the metabolism of muscle fiber caused by kidney disease. A simultaneous study of the expression of genes in the blood and muscles at the transcriptomic and / or proteomic level in catabolic situations could perhaps identify the best candidates. A biological marker able to predict early the onset of muscle atrophy before its establishment remains to be discovered.

Supporting information {#sec015}
======================
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Reviewer \#2: The Aim of the study was to demonstrate that 20S proteasome assay can predict muscle mass loss and protein energy wasting in hemodialysis patients.

The study is informative and compelling. It provides a better understanding of chronic hemodialysis patients.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewers

Editor comments

1\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reply : Because there are no restriction we have upload the minimal anonymized data set necessary to replicate our study finding as Supporting Information files

2\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Reply : Because the data are not a core part of the research being presented in our study we have remaved the phrases that refers to the data as requested (p11 l196 and p12 l216).

Reviewer 1 comments

In this manuscript Aniort et al, describes the role of C20s proteasome assay as a biomarker for the diagnosis of low muscle loss and PEW (protein energy wasting) in hemodialysis patients. For this purpose, they performed an ELISA to measure the 20S subunit in the blood of these patients but authors found out that C20s proteasome levels didn't correlate with patients' nutritional markers or clinical outcomes at baseline.

Major flaws

As authors already mentioned in the manuscript, the number of patients is too low.

For this reason, it is difficult to assess the statistic power of this analysis.

I would suggest to increase the number of cases and reperform the statistic.

Reply: We are aware that the number of patients analyzed is low. Unfortunately this clinical study has been completed to date and we cannot include new patients. Power to detect a correlation between two variables can be calculated. We used the triangular sequential test proposed by Rasch et al. Results were added in the discussion (p15 l285). The number of patients is too low for subgroups or multivariate analysis. However, we believe that we have sufficient statistical power (\> 80%) to consider that circulating proteasome is not marker efficient enough to be usable in clinical practice.

Minor flaws

1\. In Fig. 1 change "N" with "n" to maintain consistency.

This was corrected.

2\. The work done by Aniort et al is of value but need further evidences. To improve the discussion, I want to suggest other ways to give an explanation on the data of ESRD subjects suffering from both diabetes and PEW. In this case the metabolic disorder of this court of patients might influence the levels of C20s proteasome subunit in some way unlike other patients affected by other comorbidity. In this perspective, an interesting point of view about this topic can be found in this paper (Niewczas M et al, Nat Med, 2019). The evidences contained in this work could be an input to wondering about new biomarkers that could correlate with PEW in a court of ESRD and diabetic patients at least.

Reply : We thank the reviewer for the comment. Indeed proteomic or transcriptomic are interesting ways to discover a panel of biomarkers predictive of muscle atrophy. We have added this reflection and the reference given as an example by reviewer 1 in the discussion part (p14 l274).

Reviewer \#2:

The Aim of the study was to demonstrate that 20S proteasome assay can predict muscle mass loss and protein energy wasting in hemodialysis patients.

The study is informative and compelling. It provides a better understanding of chronic hemodialysis patients.
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Dear Dr. Aniort,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Paolo Fiorina, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0236948.r004

Acceptance letter

Fiorina

Paolo

Academic Editor

© 2020 Paolo Fiorina

2020

Paolo Fiorina

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

20 Jul 2020

PONE-D-20-07087R1

Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients

Dear Dr. Aniort:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Paolo Fiorina

Academic Editor

PLOS ONE
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